Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs), general research and medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the project.
## Competitive Grant Program Eligibility

### Geographic Scope

- Africa
- Middle East
- Asia
- Latin America

### Applicant Eligibility Criteria

To be eligible:

- The principal investigator (PI) and institution must be based in one of the eligible regions noted above.
- The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent).
- Applicant must be affiliated with a host institution.
- Both early career and experienced investigators are encouraged to apply and consideration will be given to all proposals meeting the selection criteria.
- If the project involves multiple departments within an institution and/or between different institutions/organizations/associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.

## Requirements

<table>
<thead>
<tr>
<th>Date RFP Issued</th>
<th>December 4, 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area</td>
<td>Oncology – Breast Cancer</td>
</tr>
</tbody>
</table>
| Area of Interest Focus | The intent of this Request for Proposal (RFP) is to invite investigators from across the eligible countries listed above to submit innovative proposals focusing in the following areas in breast cancer:  
  - Real-word studies (e.g., retrospective studies) to understand breast cancer epidemiology, patient population, and treatment landscape including adaptation of international guidelines to local practice, or genetic testing practices (such as BRCA) |
Studies to understand clinical outcomes in patients with HR+, HER2- metastatic breast cancer of various social economic status (e.g. patients with no or limited accessibility to medicines and health care services vs those with accessibility)

- Clinical studies incorporating correlative/biomarker component using paired biopsy samples, e.g. pre- and post- treatment; and/or at disease progression, ctDNA, to identify potential mechanisms of resistance to palbociclib or talazoparib treatment

- Evaluation of optimal clinical and/or nursing management approaches during palbociclib treatment that improves patients' treatment compliance, patients' convenience, and/or patient-reported outcomes, e.g. use of digital technology such as mobile applications

- Breast Cancer related programs with clearly defined outcome measures* to improve medical knowledge and patient care, for example community outreach

Note: This Request for Proposals is not designed to support large randomized interventional studies. Avelumab proposals are excluded from this RFP.

*This type of research proposal should be investigator-led educational programs for healthcare professionals to improve medical knowledge and patient care, with clearly-defined local or community-based metrics and outcomes measures. Education must use a research framework to measure improvement or patient impact at the clinical or community level.

### Expected Approximate Monetary Range of Grant Applications

- A total of $3 million USD is allocated to this grants program.
- Applications will be reviewed by an independent review panel. Up to 15 projects will be selected for funding.
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the external review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the approval notification.
### Key Dates
- RFP release date: December 4, 2019
- Full Proposal due date: April 7, 2020
  
  [Please note the deadline is midnight Eastern Time (New York, GMT - 5).]
- Anticipated Full Proposal Notification Date: September 18, 2020

**NOTE:** Grant funding will be distributed following execution of fully signed Letter of Agreement. Prior to awarding any proposal applicants must comply with Pfizer’s Internal Policies and processes, as well as local law and regulation.

### How to Apply
- Please go to [www.cybergrants.com/pfizer/Research](http://www.cybergrants.com/pfizer/Research) and sign in. First-time users should click “REGISTER NOW”.

**Requirements for submission:**
- Select the following Competitive Grant Program Name: **2020 Breast Cancer Competitive Research for AfME, Asia, LatAm**
- Complete all required sections of the online application. See Appendix A for additional details. All applications must be in English.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

### Questions:
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jessica Romano ([Jessica.Romano@pfizer.com](mailto:Jessica.Romano@pfizer.com)), with the subject line “2020 Breast Cancer Competitive Research for AfME, Asia, LatAm.”

### Mechanism by which Applicants will be Notified:
- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.
Appendix A
Full Proposal/Protocol

Applications will be accepted via the online portal. When uploading your Full Proposal/Protocol please ensure the following elements are being addressed:

<table>
<thead>
<tr>
<th>Goals and Objectives</th>
<th>• Provide the main goal of the project and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment of Need for the Project</td>
<td>• This should reflect your project rationale. Provide a brief description of the medical/scientific question and the rationale of how this project addresses the question</td>
</tr>
<tr>
<td>Target Audience</td>
<td>• Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population • Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population</td>
</tr>
<tr>
<td>Project Design and Methods</td>
<td>• Describe concisely the research or education design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan</td>
</tr>
<tr>
<td>Innovation</td>
<td>• Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project</td>
</tr>
<tr>
<td>Evaluation and Outcomes</td>
<td>• Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures • Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines</td>
</tr>
<tr>
<td>Anticipated Project Timeline</td>
<td>• Provide an anticipated timeline for your project including project start/end dates</td>
</tr>
<tr>
<td>Additional Information</td>
<td>• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here • Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant’s career</td>
</tr>
</tbody>
</table>
### Organization Detail

- This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and “other”]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project.

### References

- Bibliography of relevant references.